Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Updated real-world outcomes with brentuximab vedotin in lymphoma patients: A multicenter, retrospective study from China

View Full Paper
Ask AI
Bookmark
Share

Authors

MZMingzhi ZhangChinese Academy of SciencesYBYanliang BaiZhengzhou UniversityKZKeshu ZhouWuhan University

Discussion

Loading...

Member takes

Overview

Multicenter study shows brentuximab vedotin improves survival and response rates in CD30-positive lymphoma patients, indicating effective treatment options.

Key Points

  • To report the effectiveness and safety of brentuximab vedotin in patients with CD30-positive lymphoma in a real-world setting.
  • Multicenter, retrospective study across three centers in central China
  • Involvement of 252 patients diagnosed with CD30-positive lymphoma
  • Evaluation of treatment outcomes after brentuximab vedotin therapy
  • Overall response rate (ORR) of 67.1% and complete response (CR) rate of 39.7% observed
  • 1-year overall survival (OS) rate of 87.1% and 2-year OS rate of 83.8%
  • Adverse events reported in 85.7% of patients, with anemia and leukopenia being the most common

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e296https://doi.org/10.1182/blood-2025-7206
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis2025
  2. 2Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma2025
  3. 3Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study2025
  4. 4Real-world Effectiveness and Safety of Brentuximab Vedotin: A Retrospective Cohort Study from a Tertiary Care Hospital2026
  5. 5Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data2024